Haemonetics Corporation Share Price
Stocks
HAE
US4050241003
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
01:30:02 05/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 102.92 USD | +0.07% |
|
-1.00% | +28.41% |
| 19/08 | Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating | MT |
| 19/08 | Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma | MT |
| Market Cap | 468.26Cr 402.93Cr 379.1Cr 346.31Cr 647.85Cr 44TCr 649.61Cr 4.48TCr 1.74TCr 23TCr 1.76TCr 1.72TCr 73TCr | P/E 2027 * |
26x | P/E 2028 * | 22.8x |
|---|---|---|---|---|---|
| Enterprise Value | 534.46Cr 459.9Cr 432.7Cr 395.27Cr 739.44Cr 50TCr 741.45Cr 5.11TCr 1.98TCr 26TCr 2.01TCr 1.96TCr 83TCr | EV / Sales 2027 * |
3.78x | EV / Sales 2028 * | 3.36x |
| Free-Float |
98.74% | Yield 2027 * |
0.97% | Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| HAE | Delayed | |
CBOE
| HAE | Real-time | |
|
Deutsche Boerse AG
| HAZ | Delayed | |
|
Börse Stuttgart
| HAZ | Delayed | |
|
Boerse Muenchen
| HAZ | Real-time | |
|
Tradegate
| HAZ | Real-time |
Last Transcript : Haemonetics Corporation
| 1 day | +0.07% | ||
| 1 week | -1.00% | ||
| Current month | -0.15% | ||
| 1 month | +23.11% | ||
| 3 months | +44.39% | ||
| 6 months | +60.24% | ||
| Current year | +28.41% |
| 1 week | 101.08 |  | 104.37 |
| 1 month | 84.88 | | 109.57 |
| Current year | 51 | | 109.57 |
| 1 year | 47.32 | | 109.57 |
| 3 years | 47.32 | | 109.57 |
| 5 years | 43.5 | | 109.57 |
| 10 years | 32.76 | | 142.11 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 16/05/2016 | |
James D'Arecca
DFI | Director of Finance/CFO | 55 | 11/04/2022 |
Frank Chan
COO | Chief Operating Officer | 56 | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Kroll
BRD | Director/Board Member | 73 | 01/01/2006 |
| Director/Board Member | 62 | 16/05/2016 | |
Robert Abernathy
BRD | Director/Board Member | 71 | 18/10/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 24/07/26 | Free | Director | 2,538 | 0.0056% | ||
| 24/07/26 | Free | Director | 2,538 | 0.0056% | ||
| 24/07/26 | Free | Director | 2,538 | 0.0056% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.07% | -1.00% | +89.26% | +17.97% | 468.26Cr | |
| -0.42% | -3.68% | -18.51% | +7.39% | 19TCr | |
| +1.15% | +3.22% | +1.37% | +17.42% | 12TCr | |
| -1.86% | +2.77% | +13.15% | +91.44% | 6.32TCr | |
| -1.31% | -1.09% | +17.67% | +43.65% | 5.17TCr | |
| -1.54% | -2.52% | -3.98% | -32.30% | 5.03TCr | |
| -2.02% | -3.22% | +9.18% | -12.39% | 3.32TCr | |
| 0.00% | +3.71% | - | - | 3.21TCr | |
| -0.81% | +0.74% | +35.59% | -15.78% | 2.39TCr | |
| -1.44% | -4.21% | -8.07% | +11.30% | 2.3TCr | |
| Average | -0.82% | -0.27% | +15.07% | +14.30% | 5.9TCr | |
| Weighted average by Cap. | -0.55% | +0.01% | -0.67% | +16.93% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 141.48Cr 121.74Cr 114.54Cr 104.64Cr 195.74Cr 13TCr 196.28Cr 1.35TCr 525.23Cr 6.85TCr 531.27Cr 519.68Cr 22TCr | 148.91Cr 128.13Cr 120.56Cr 110.13Cr 206.02Cr 14TCr 206.58Cr 1.42TCr 552.8Cr 7.21TCr 559.16Cr 546.96Cr 23TCr |
| Net income | 18Cr 15Cr 14Cr 13Cr 25Cr 1.68TCr 25Cr 169.74Cr 66Cr 859.47Cr 67Cr 65Cr 2.77TCr | 21Cr 18Cr 17Cr 15Cr 29Cr 1.96TCr 29Cr 198.26Cr 77Cr 1TCr 78Cr 76Cr 3.23TCr |
| Net Debt | 66Cr 57Cr 54Cr 49Cr 92Cr 6.25TCr 92Cr 633.35Cr 245.77Cr 3.21TCr 248.59Cr 243.17Cr 10TCr | 33Cr 28Cr 26Cr 24Cr 45Cr 3.09TCr 45Cr 312.96Cr 121.44Cr 1.58TCr 122.84Cr 120.16Cr 5.11TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | $102.92 | +0.07% | 4,25,087 |
| 03/26/03 | $102.85 | -0.07% | 6,02,060 |
| 02/26/02 | $102.92 | +0.95% | 7,77,672 |
| 01/26/01 | $101.95 | -1.09% | 6,33,647 |
| 31/26/31 | $103.07 | -0.86% | 4,94,691 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HAE Stock
Select your edition
All financial news and data tailored to specific country editions
